10 Amendments of Kosma ZŁOTOWSKI related to 2020/2071(INI)
Amendment 9 #
Draft opinion
Recital A a (new)
Recital A a (new)
A a. whereas the European Commission's response to the COVID-19 pandemic was late and insufficient, and the burden of fighting the coronavirus was mainly on the Member States;
Amendment 12 #
Draft opinion
Recital B a (new)
Recital B a (new)
B a. whereas free competition in the road transport sector, the absence of administrative barriers and easy access to transport services, including cabotage, play a crucial role in ensuring an adequate level of supply of medicines and medical devices and preventing their shortages;
Amendment 17 #
Draft opinion
Recital C a (new)
Recital C a (new)
C a. whereas ensuring patient access is one of the core objectives of the Union and the WHO, and of the Sustainable Development Goals, and whereas patients rely on equitable and sustainable access to medicines based on a sustainable, competitive, multi-source and well- functioning single market;
Amendment 21 #
Draft opinion
Recital C b (new)
Recital C b (new)
C b. whereas the COVID-19 pandemic demonstrated the importance of coordination between EU policies and department to promptly and efficiently react to emergencies as well as to prevent medicines shortages, and to mitigate them in case they occur;
Amendment 24 #
Draft opinion
Recital C c (new)
Recital C c (new)
C c. whereas the COVID-19 pandemic stressed that European coordination among the EU institutions, the Member States, regulators and pharmaceutical supply chain experts is vital to respond to health crisis and to supply disruption such as shortages of medicines in all policy areas;
Amendment 35 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1 a. Calls on the Commission to coordinate a European response to medicines shortages to ensure equitable and sustainable access to medicines; believes that a coordinated EU response is of utmost importance to avoid spillover effects of individual and uncoordinated national measures to address medicines shortages and ensure the right of patients to universal, equitable, affordable, effective, safe and timely access to essential medicines, as well as to guarantee the sustainability of the EU public healthcare systems;
Amendment 60 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5 a. Calls on the Commission to provide financial and organisational support to the Member States and transport operators in urgent cases, to prioritise and provide reserved space in all cargoes for essential goods (such as medicines, active pharmaceutical ingredients, medical equipment, etc.)
Amendment 69 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6 a. Underlines that restricting the supply of transport services by creating market or administrative barriers poses a serious threat to the continuity of supply of medicines, medical devices and other medical products and may be a reason for their shortage in the common market;
Amendment 77 #
Draft opinion
Paragraph 7
Paragraph 7
7. Notes that the COVID-19 outbreak has laid barmade the weaknesses of the European production systemgoods distribution system during extraordinary circumstances, highlighting the importance of timely deliveringy of medicines swiftly in urgent and exceptional circumstances that could ariseoccur in the future.;
Amendment 81 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7 a. Underlines that flexibility in the approach to rules on working and rest time in road transport had played an essential role in making the distribution chain for medicines and medical devices more efficient when the COVID-19 pandemic erupted; stresses that European rules in this area should take greater account of such emergencies and provide for flexibility in the approach to working time issues;